Minimal common regions observed in >10% of the cases of RS and CLL phase
| Diagnosis . | Lesion . | Cytoband . | Frequency, % . | Start* . | Size, Kb* . | Candidate genes . | No. genes† . |
|---|---|---|---|---|---|---|---|
| RS | Gains | ||||||
| 12 | 27 | 1.00E+00 | 1.34E+05 | >100 | |||
| 3q21.1-q29 | 13 | 1.23E+08 | 7.44E+04 | >100 | |||
| 8q21.2-q24.3 | 13 | 8.57E+07 | 6.06E+04 | MYC | >100 | ||
| 15q21.3-q26.3 | 15 | 5.64E+07 | 4.60E+04 | >100 | |||
| 18q21.2-q23 | 13 | 5.15E+07 | 2.65E+04 | BCL2, NFATC1 | 97 | ||
| 1q32.1 | 15 | 2.02E+08 | 3.53E+03 | MDM4 | 60 | ||
| 1q25.3 | 15 | 1.81E+08 | 1.76E+03 | 11 | |||
| 1q21.1-q32.1 | 15 | 1.46E+08 | 6.05E+04 | >100 | |||
| 11q24.3-q25 | 13 | 1.29E+08 | 6.34E+03 | 32 | |||
| 11q22.1-q22.3 | 13 | 1.02E+08 | 1.98E+03 | 18 | |||
| 13q31.3 | 12 | 9.28E+07 | 1.65E+02 | MIR17HG | 1 | ||
| Losses | |||||||
| 17p13.3-p11.2 | 33 | 5.26E+02 | 2.01E+04 | TP53 | >100 | ||
| 13q14.2-q14.3 | 28 | 4.99E+07 | 1.86E+03 | DLEU2, MIR15A, MIR16 | 20 | ||
| 9p21.3 | 22 | 2.13E+07 | 1.30E+03 | CDKN2A | 17 | ||
| 7q33 | 17 | 1.35E+08 | 1.76E+03 | 9 | |||
| 8p21.2 | 18 | 2.35E+07 | 7.45E+02 | 4 | |||
| 8p23.1 | 18 | 1.26E+07 | 8.14E+01 | 4 | |||
| 9q33.2-q34.3 | 15 | 1.23E+08 | 1.78E+04 | >100 | |||
| 14q32.11-q32.33 | 15 | 9.19E+07 | 1.40E+04 | >100 | |||
| 19p13.2-p13.11 | 15 | 1.29E+07 | 6.17E+03 | >100 | |||
| 9q21.33-q34.3 | 13 | 8.90E+07 | 5.21E+04 | >100 | |||
| 1q42.12-q42.3 | 15 | 2.26E+08 | 1.03E+04 | 90 | |||
| 1p36.33-p36.23 | 15 | 6.17E+04 | 8.75E+03 | TNFRSF14 | >100 | ||
| 4p14 | 13 | 3.87E+07 | 2.23E+03 | 24 | |||
| 7q32.3-q36.3 | 13 | 1.31E+08 | 2.81E+04 | >100 | |||
| 19p | 12 | 9.09E+04 | 2.80E+04 | TNFSF9 | >100 | ||
| 6p25.2-p24.2 | 12 | 3.43E+06 | 8.12E+03 | 49 | |||
| 11q22.3-q23.3 | 12 | 1.04E+08 | 1.23E+04 | ATM, MIR24B, MIR34C | 86 | ||
| CLL phase | Gains | ||||||
| 12 | 29 | 1.00E+00 | 1.34E+05 | >100 | |||
| 2p25.2-p12 | 14 | 1.28E+04 | 8.18E+04 | MYCN, REL | >100 | ||
| 21q22.3 | 11 | 4.73E+07 | 8.26E+02 | 14 | |||
| Losses | |||||||
| 17p13.3-p11.2 | 32 | 5.26E+02 | 1.94E+04 | TP53 | >100 | ||
| 13q14.2-q14.3 | 32 | 4.97E+07 | 2.14E+03 | DLEU2, MIR15A, MIR16 | 83 | ||
| 15q14-q15.3 | 14 | 3.97E+07 | 4.13E+03 | MGA | 83 | ||
| 8p23.3-q13.2 | 11 | 4.64E+04 | 6.81E+04 | TNFRSF10A, TNFRSF10B | >100 | ||
| 11q14.1-q23.3 | 11 | 7.99E+07 | 3.69E+04 | ATM, BIRC3, MIR34B, MIR34C | >100 | ||
| 18p | 11 | 1.15E+04 | 1.50E+04 | >100 | |||
| 20p11.23 | 11 | 1.93E+07 | 5.38E+02 | 8 |
| Diagnosis . | Lesion . | Cytoband . | Frequency, % . | Start* . | Size, Kb* . | Candidate genes . | No. genes† . |
|---|---|---|---|---|---|---|---|
| RS | Gains | ||||||
| 12 | 27 | 1.00E+00 | 1.34E+05 | >100 | |||
| 3q21.1-q29 | 13 | 1.23E+08 | 7.44E+04 | >100 | |||
| 8q21.2-q24.3 | 13 | 8.57E+07 | 6.06E+04 | MYC | >100 | ||
| 15q21.3-q26.3 | 15 | 5.64E+07 | 4.60E+04 | >100 | |||
| 18q21.2-q23 | 13 | 5.15E+07 | 2.65E+04 | BCL2, NFATC1 | 97 | ||
| 1q32.1 | 15 | 2.02E+08 | 3.53E+03 | MDM4 | 60 | ||
| 1q25.3 | 15 | 1.81E+08 | 1.76E+03 | 11 | |||
| 1q21.1-q32.1 | 15 | 1.46E+08 | 6.05E+04 | >100 | |||
| 11q24.3-q25 | 13 | 1.29E+08 | 6.34E+03 | 32 | |||
| 11q22.1-q22.3 | 13 | 1.02E+08 | 1.98E+03 | 18 | |||
| 13q31.3 | 12 | 9.28E+07 | 1.65E+02 | MIR17HG | 1 | ||
| Losses | |||||||
| 17p13.3-p11.2 | 33 | 5.26E+02 | 2.01E+04 | TP53 | >100 | ||
| 13q14.2-q14.3 | 28 | 4.99E+07 | 1.86E+03 | DLEU2, MIR15A, MIR16 | 20 | ||
| 9p21.3 | 22 | 2.13E+07 | 1.30E+03 | CDKN2A | 17 | ||
| 7q33 | 17 | 1.35E+08 | 1.76E+03 | 9 | |||
| 8p21.2 | 18 | 2.35E+07 | 7.45E+02 | 4 | |||
| 8p23.1 | 18 | 1.26E+07 | 8.14E+01 | 4 | |||
| 9q33.2-q34.3 | 15 | 1.23E+08 | 1.78E+04 | >100 | |||
| 14q32.11-q32.33 | 15 | 9.19E+07 | 1.40E+04 | >100 | |||
| 19p13.2-p13.11 | 15 | 1.29E+07 | 6.17E+03 | >100 | |||
| 9q21.33-q34.3 | 13 | 8.90E+07 | 5.21E+04 | >100 | |||
| 1q42.12-q42.3 | 15 | 2.26E+08 | 1.03E+04 | 90 | |||
| 1p36.33-p36.23 | 15 | 6.17E+04 | 8.75E+03 | TNFRSF14 | >100 | ||
| 4p14 | 13 | 3.87E+07 | 2.23E+03 | 24 | |||
| 7q32.3-q36.3 | 13 | 1.31E+08 | 2.81E+04 | >100 | |||
| 19p | 12 | 9.09E+04 | 2.80E+04 | TNFSF9 | >100 | ||
| 6p25.2-p24.2 | 12 | 3.43E+06 | 8.12E+03 | 49 | |||
| 11q22.3-q23.3 | 12 | 1.04E+08 | 1.23E+04 | ATM, MIR24B, MIR34C | 86 | ||
| CLL phase | Gains | ||||||
| 12 | 29 | 1.00E+00 | 1.34E+05 | >100 | |||
| 2p25.2-p12 | 14 | 1.28E+04 | 8.18E+04 | MYCN, REL | >100 | ||
| 21q22.3 | 11 | 4.73E+07 | 8.26E+02 | 14 | |||
| Losses | |||||||
| 17p13.3-p11.2 | 32 | 5.26E+02 | 1.94E+04 | TP53 | >100 | ||
| 13q14.2-q14.3 | 32 | 4.97E+07 | 2.14E+03 | DLEU2, MIR15A, MIR16 | 83 | ||
| 15q14-q15.3 | 14 | 3.97E+07 | 4.13E+03 | MGA | 83 | ||
| 8p23.3-q13.2 | 11 | 4.64E+04 | 6.81E+04 | TNFRSF10A, TNFRSF10B | >100 | ||
| 11q14.1-q23.3 | 11 | 7.99E+07 | 3.69E+04 | ATM, BIRC3, MIR34B, MIR34C | >100 | ||
| 18p | 11 | 1.15E+04 | 1.50E+04 | >100 | |||
| 20p11.23 | 11 | 1.93E+07 | 5.38E+02 | 8 |